Enliven Therapeutics, Inc. (ELVN), Friday announced the underwritten public offering of about 8.4 million shares of its common stock at $19.66 per share, and pre-funded warrants to purchase upto around 1.8 million shares of its common stock at $19.659 per pre-funded warrant.
The offering, expected to raise a total of approximately $200 million, is set to close on or about June 16, 2025.
In addition to this offering, the company has also granted the underwriters a 30-day option to purchase upto an additional about 1.5 million shares of its common stock at the public offering price.
Currently, ELVN is trading at $20.09, up 2.21 percent on the Nasdaq.
For comments and feedback contact: editorial@rttnews.com
Business News
May 01, 2026 15:54 ET Central banks dominated the economics news flow this week with almost all major ones announcing their latest policy decisions and many boosted expectations for a rate hike in June. In other news, several countries released the preliminary data for first quarter economic growth. In the U.S., comments by Fed Chair Jerome Powell were also in focus as his term ends this month.